# US 2003/0216335 A1 · Method and reagent for the modulation of female reproductive diseases and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216335 A1
- Document ID: US20030216335A1
- Status: Published application
- Kind: A1
- Application number: 10/306,747
- Filed: 2002-11-27
- Published: 2003-11-20
- Earliest claimed: 2001-11-30
- Inventors: Jennifer Lockridge; Pamela Pavco; Gilad Gordon
- Web page: https://patentgrep.com/patent/US20030216335A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 47/54: the modifying agent being an organic compound
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C12N 15/1132: {against retroviridae, e.g. HIV}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Y 104/03003: D-Amino-acid oxidase (1.4.3.3)
- C12Y 114/19001: Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- C12Y 207/11013: Protein kinase C (2.7.11.13)
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/121: Hammerhead
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/318: where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/332: Abasic residue
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/53: partially self-complementary or closed
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Y: ENZYMES

## Abstract

The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

## Claims

### Claim 1

A method for treating endometriosis in a mammalian subject comprising contacting the subject with a nucleic acid molecule that modulates the expression of VEGF, VEGFR1, VEGFR2 or combinations thereof under conditions suitable for said treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule.

### Claim 3 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is an antisense nucleic acid molecule.

### Claim 4 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is a dsRNA nucleic acid molecule.

### Claim 5 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is a nucleic acid aptamer.

### Claim 6 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule comprises a sequence having SEQ ID NO: 13.

### Claim 7 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule has an endonuclease activity selected from the group consisting of cleavage of RNA encoded by a VEGFRI gene, cleavage of RNA encoded by a VEGFR2 gene and cleavage of RNA encoded by a VEGFR1 gene and RNA encoded by a VEGFR2 gene.

### Claim 8 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in a hammerhead configuration.

### Claim 9 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in an Inozyme configuration.

### Claim 10 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in a Zinzyme configuration.

### Claim 11 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in a DNAzyme configuration.

### Claim 12 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in a G-cleaver configuration.

### Claim 13 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is in an Amberzyme configuration.

### Claim 14 (depends on 2)

The method of claim 2, wherein said enzymatic nucleic acid molecule is an allozyme.

### Claim 15 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule is chemically synthesized.

### Claim 16 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule comprises at least one 2′-sugar modification.

### Claim 17 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule comprises at least one nucleic acid base modification.

### Claim 18 (depends on 1)

The method of claim 1, wherein said nucleic acid molecule comprises at least one phosphate backbone modification.

### Claim 19 (depends on 1)

The method of claim 1, wherein said mammalian subject is a human.

### Claim 20

A method for treating a endometriosis in a mammalian subject comprising administering to the subject a nucleic acid molecule that modulates the expression of VEGF, VEGFR1, VEGFR2 or combinations thereof under conditions suitable for said treatment

### Claim 21 (depends on 20)

The method of claim 20 wherein said administration is in the presence of a delivery reagent.

### Claim 22 (depends on 21)

The method of claim 21, wherein said delivery reagent is a lipid.

### Claim 23 (depends on 22)

The method of claim 22, wherein said lipid is a cationic lipid.

### Claim 24 (depends on 22)

The method of claim 22, wherein said lipid is a phospholipid.

### Claim 25 (depends on 21)

The method of claim 21, wherein said delivery reagent is a liposome.

### Claim 26 (depends on 20)

The method of claim 20, wherein said administration includes treatment with one or more other therapies.

### Claim 27 (depends on 26)

The method of claim 26, wherein said other therapies are selected from the group consisting of gonadotropin releasing hormone (GnRH) agonists, Leuprolide Acetate (Lupron Depot), naferalin acetate (Synarel), goserelin acetate (Zolodex), buserelin acetate (Suprefact), Danazol, and oral contraceptives.
